kairoby Opportune Labs

Humanin

Humanin is a short peptide studied for cell-survival signaling and mitochondrial biology. Much of its reputation comes from experimental models and associations between naturally occurring levels and health.

Investigational / researchPreclinical and observational evidence
Kairo editorial · Sources reviewed September 9, 20264 sources
On this page
  1. Overview
  2. What the evidence shows
  3. Safety
  4. Common questions
  5. Questions for your clinician
  6. Sources

This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.

Overview

Product & regulatory status

The sources here support a research role, rather than an established replacement or anti-aging treatment.

Cell survival research

The original screening work found protection against several Alzheimer-related cellular insults, while other toxic models were not protected. This indicates a selective research effect rather than universal neuronal protection. [1]

What the evidence shows

Initial neuronal experiments

Researchers identified Humanin through experiments in which it protected cultured neuronal cells from several Alzheimer-related insults. Protection in these experimental systems is not proof of preventing dementia in people. [1]

Lifespan research

A 2020 study connected Humanin with lifespan and healthspan biology across experimental systems and examined human associations. An association between endogenous levels and disease does not show that administering Humanin will reverse the disease. [2]

What remains unknown

Clinical benefit from externally administered Humanin, long-term safety, and which variants might be comparable remain unresolved in this guide.

Safety

Natural occurrence is not proof of supplement safety

The foundational experiments measured selected cell-survival effects. They did not establish a safe long-term Humanin product for people or compatibility with other growth-related compounds. [1]

Exact peptide identity matters

The founding work tested Humanin and changes to its peptide sequence in cellular systems. Findings for a modified analog should not be treated as product specifications for native Humanin. [1]

Understanding product quality

Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]

When to seek urgent help

Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]

A starting point for discussion

This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.

Common questions

Is a Humanin analog interchangeable with Humanin?

No. A modified research analog may behave differently. The exact molecule and study population need to match before evidence is carried across.

Questions for your clinician

Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?

Sources

  1. Humanin and neuronal cell survival experiments2001 · Original research · PubMed
  2. Humanin in experimental lifespan and healthspan research2020 · Original research · PubMed
  3. Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
  4. AnaphylaxisMedlinePlus · recognizing an emergency

Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.